Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Biomarker Development Versus Drug Development
- Sidebar: Where Do Novel Biomarkers Come From?
- Biomarkers in Drug Development
- Model Case Studies
- Biomarker Diagnostics and Progress Indicators
- Making Strategic Partnering Decisions
- Factors That Infl uence Alliances
- Partnering.....
- .....Or Not Partnering
- Common Types of Biomarker-Centric Alliances
- Whole Company Acquisition
- Affymetrix Complements Its Product Line with the Addition of Panomics
- Johnson & Johnson Acquires Amic
- Immucor Acquires BioArray Solutions
- Asset Purchase
- Collaborations
- Roche Will Work with Arcxis on Infectious Disease and Cancer
- Rosetta Genomics Worked with Columbia University to Validate its NSCLC
Test
- The European Group for the Study of Insulin Resistance Will Contribute
Samples to Metabolon
- ApoCell Will Support Pfi zer' s Phase I Clinical Trial
- Genomic Health Is Developing a Renal Cell Carcinoma Test for Pfi zer
- Licensing Opportunities
- Ipsogen Licenses to Quest Diagnostics
- Genomic Nanosystems Licenses to Sequenom
- Johns Hopkins University Licenses to Orion Genomics
- OncoMethylome Sciences Licenses to Merck KGaA
- 20/20 GeneSystems/Ortho-Clinical Diagnostics
- Government' s Vested Interest
- Conclusions and Outlook
- Trends by Therapy Area
- “Blockbuster Diagnostic” Is an Oxymoron - for the Moment
- Drug Development Is a Driver
- Growth Comes from Undersized Sectors
- Spectrum Expert Commentary:
- Ten Insights on Integrating Personalized Medicine into Pharma Business
Strategies
Sidebar
- Where Do Novel Biomarkers Come From?
Expert Commentary
- Ten Insights on Integrating Personalized Medicine into Pharma Business
Strategies, Lulu Pickering, Ph.D., Decision Resources
Tables
- 1. Use of Biomarkers in Drug Development
- 2. Valid Genomic Biomarkers in the Context of Approved Drug Labels, for
Required and Recommended Tests
- 3. Valid Genomic Biomarkers in the Context of Approved Drug Labels, for
Information Only
- 4. Whole Company Acquisitions Related to Biomarkers and Diagnostics,
November 2007- November 2008
- 5. Asset Purchase Deals Related to Biomarkers and Diagnostics, November
2007- November 2008
- 6. Select Collaborations Related to Biomarkers and Diagnostics, November
2007- November 2008
- 7. Select Licensing Opportunities Related to Biomarkers and Diagnostics,
November 2007-November 2008
- 8. Select Government-Based Alliances Related to Biomarkers and
Diagnostics, November 2007-November 2008
Figures
- 1. Drug Discovery, Development, and Approval Process
- 2. Diagnostic Technologies Can Increase Treatment Effi cacy
- 3. Cycle of Funding Gained Through Academic Research
- 4. Payer Attitudes Toward Diagnostic Regulatory Pathways
- 5. Trends in Biomarker and Diagnostics Alliances by Therapy Area, November
2007-November 2008
|
Related Report
|
View Cart
